Explicitly offers small-molecule MicroED and presents protein and peptide MicroED examples, separately from SPA services.
Secondary reporting confirms a capital event. Some databases label it Series C, but a consistent primary-source designation was not obtained; no label is imposed.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
The MicroED workflow includes crystal screening, continuous-rotation cryo-EM data collection, processing, structure solution, and CIF reporting.
The page specifically identifies Proteinase K and FUS LC examples as MicroED, while GPCR and virus examples are labeled SPA.
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| MicroED / 3D ED service capabilities | Determined by the submitted sample and research question · Not applicable; service capability | Services / platform | Not applicable; not a human clinical program |
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
No cataloged update explicitly mentions this company.
This article explores how Microcrystal Electron Diffraction (MicroED) is set to revolutionize drug polymorph research workflows. Drawing upon recent news, official websites, and LinkedIn updates from Crystal Pharmatech and Eldico, it clearly distinguishes between verified facts, industry viewpoints, and information pending verification.
Direct Electron lists a REyes webinar for November 10, 2026, at noon Eastern Time. It will discuss diffraction-guided screening, automated acquisition and structure solution, including integration with SerialEM.
Crystal Pharmatech’s November 4 announcement confirms ED-1 service in Suzhou. Its service page describes integration with solid-form screening for small crystals and pharmaceutical solid forms.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.